← Back to Search

Ancillary-correlative (renal tumor classification, biology) for Wilms Tumor

N/A
Recruiting
Led By Elizabeth A Mullen
Research Sponsored by Children's Oncology Group
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years from study enrollment
Awards & highlights

Summary

This research trial studies kidney tumors in younger patients. Collecting and storing samples of tumor tissue, blood, and urine from patients with cancer to study in the laboratory may help doctors learn more about changes that occur in deoxyribonucleic acid (DNA) and identify biomarkers related to cancer.

Eligible Conditions
  • Wilms Tumor
  • Renal Tumor of Infancy
  • Metanephric Stromal Tumor
  • Kidney Cancer
  • Kidney Cell Carcinoma
  • Congenital Mesoblastic Nephroma
  • Rhabdoid Tumor
  • Renal Cell Carcinoma
  • Angiolipoma
  • Cystic Nephroma
  • Clear Cell Sarcoma of the Kidney
  • Nephroblastoma
  • Diffuse Hyperplastic Perilobar Nephroblastomatosis
  • Extrarenal Rhabdoid Tumor
  • Kidney Carcinoma
  • Kidney Tumors
  • Kidney Oncocytoma
  • Metanephric Adenofibroma
  • Metanephric Adenoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years from study enrollment
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years from study enrollment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Event-free survival
Overall survival
Secondary outcome measures
Loss of heterozygosity (LOH testing discontinued as of April 2014)

Trial Design

1Treatment groups
Experimental Treatment
Group I: Ancillary-correlative (renal tumor classification, biology)Experimental Treatment2 Interventions
Tumor tissue, blood, and urine samples are collected for research studies, including immunohistochemistry. CT scans and MRIs are also performed. Loss of heterozygosity analyses (chromosome 1p and 16q) are performed by extraction of DNA. DNA polymorphisms are assayed by polymerase chain reaction using standard methodology. Leftover specimens are archived for future studies. (LOH and INI1 testing discontinued as of April 2014)

Find a Location

Who is running the clinical trial?

Children's Oncology GroupLead Sponsor
456 Previous Clinical Trials
231,787 Total Patients Enrolled
30 Trials studying Wilms Tumor
11,682 Patients Enrolled for Wilms Tumor
National Cancer Institute (NCI)NIH
13,748 Previous Clinical Trials
40,951,401 Total Patients Enrolled
54 Trials studying Wilms Tumor
13,408 Patients Enrolled for Wilms Tumor
Elizabeth A MullenPrincipal InvestigatorChildren's Oncology Group
2 Previous Clinical Trials
2,464 Total Patients Enrolled
2 Trials studying Wilms Tumor
2,464 Patients Enrolled for Wilms Tumor
~5333 spots leftby Jan 2100
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top